Surgical management of gastric cancer in the era of immunotherapy
10.3760/cma.j.cn112139-20240220-00075
- VernacularTitle:免疫治疗时代下的胃癌外科
- Author:
Ziyu LI
1
;
Yongning JIA
;
Xinxing LU
;
Guangmin GUAN
;
Qi WANG
Author Information
1. 北京大学肿瘤医院胃肠肿瘤中心 北京市肿瘤防治研究所 恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Keywords:
Stomach neoplasms;
Surgical procedures, operative;
Function-preserving surgery;
Immune checkpoint Inhibitors;
Neoadjuvant therapy
- From:
Chinese Journal of Surgery
2024;62(5):353-358
- CountryChina
- Language:Chinese
-
Abstract:
With the widespread application of immune checkpoint inhibitors, chemotherapy combined with immunotherapy has shown promising efficacy in the treatment of various cancers. Especially gastric cancer, this strategy is gradually expanding from first-line treatment in advanced stages to perioperative management. Compared to neoadjuvant chemotherapy alone, the combined approach not only improves pathological regression but also leads to better downstaging, which is particularly significant in gastric cancer subsets that are HER2-positive, mismatch repair deficient, PD-L1 combined positive score ≥5, or EB virus-positive. This combined treatment has made it possible to reduce the extent of gastrectomy, perform function-preserving surgeries, or even consider non-surgical strategies. Currently, exploring the optimal protocols for combining immune checkpoint inhibitors with chemotherapy, identifying potential indications for function-preserving surgery, improving surgical methods, and developing non-surgical strategies represent key issues in the surgical management of gastric cancer in the era of immunotherapy.
